PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Reports Fourth Quarter and Full Year 2020 Results

PPD Reports Fourth Quarter and Full Year 2020 Results

PPD went public in February 2020, raising $1.6 billion in gross proceeds in a U.S. IPO. The firm provides contract research services to biopharmaceutical and research organizations worldwide.

PPD May See Durable Growth From Virus Study Revenue

PPD, Inc. (PPD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why PPD, Inc. (PPD) Might be Well Poised for a Surge

The AZEK Company

Flying Eagle Acquisition Corp.

Social Capital Hedosophia Holdings Corp. II 

Social Capital Hedosophia Holdings Corp. III

Jaws Acquisition Corp

Laird Superfood

Pershing Square Tontine Holdings

Reynolds Consumer Products

XPeng

The year has seen more than 370 companies go public, so finding the 10 best IPOs to invest in won't be easy. Here are the top contenders.

Buy And Hold The Top 10 IPOs Of 2020 For Long-Term Gains

DraftKings

Horizon Pharma

Cloudflare

Ceridian HCM Holding Inc.

Most experienced investors are well aware of the major indexes that compose the equity markets.

5 Stocks Set to Score From MSCI Index Rebalancing

PPD, Inc. (PPD) CEO David Simmons on Q3 2020 Results - Earnings Call Transcript

Investor sentiment remains strong for PPD, as shareholders have enjoyed almost 250% upside since the selloff in March. The stock has bounced away from support 7 times since then, in a narrow ascending channel with low downside, although valuation remains low with an -86% value gap.

PPD Continues Its Climb With Potential For Further Uptick

ASLAN Pharmaceuticals Ltd - ADR

Ligand Pharmaceuticals

Eli Lilly

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million Deal

PPD saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

PPD Looks Good: Stock Adds 5.2% in Session

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Pricing of Secondary Offering of Shares of Common Stock

PPD Announces Pricing of Secondary Offering of Shares of Common Stock

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD Announces Secondary Offering of Shares of Common Stock.

PPD Announces Secondary Offering of Shares of Common Stock

LOS ANGELES, Aug. 20, 2020 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced it closed an oversubscribed $40 million funding round.

Science 37® Raises $40 Million to Extend Its Leadership in the Decentralized Clinical Trial Market

PPD beats the Street by $84.5 million on revenues, but misses EPS by $0.15.

PPD: Gains 10% This Month From Q2 Results On 8.16% FCF Margin, But Valuation Remains Behind

PPD, Inc. (PPD) CEO David Simmons on Q2 2020 Results - Earnings Call Transcript

WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today announced it has signed a new three-year agreement with Pfizer Inc. to provide drug development services to advance Pfizer’s portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for additional two-year periods. Financial details of the agreement were not disclosed.

PPD Signs New Service Agreement with Pfizer

Livongo Health Inc

Royalty Pharma

Warner Music Group

ZoomInfo Technologies

The Renaissance IPO Index is up 37.7% year to date compared to -1.3% for the S&P 500. Here are seven new stocks to buy from this index.

7 New Stocks to Buy for 2021 and Beyond

PPD's (PPD) CEO David Simmons on Q1 2020 Results - Earnings Call Transcript

PPD (NASDAQ: PPD) shares are trading higher on Friday, after Morgan Stanley maintained an Overweight rating and raised its price target from $26 to $30.

Why PPD's Stock Is Trading Higher Today

PPD - Fully Valued Drug Development Company

PPD Inc. (NASDAQ: PPD) made an exciting entrance to the market Thursday.

PPD Proves Optimistic in IPO Debut

PPD Inc. shares  soared 14% in their trading debut Thursday, after the drug research company's initial public offering priced at the high end of its $24 to $27 price range.

News for PPD Stock (PPD)